(Llovet et al., 2021) More recently, a combination therapy of the PD-L1 blocking antibody Atezolizumab and the VEGF neutralizing antibody Bevacizumab resulted in an improvement of overall and progression-free survival superior to sorafenib, and thus represent the current standard of care as first line therapy in patients with advanced HCC. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.